National Research (NASDAQ:NRC) Price Target Raised to $26.00

National Research (NASDAQ:NRC) had its target price boosted by Citizens Jmp from $23.00 to $26.00 in a report issued on Wednesday morning,Benzinga reports. They currently have a market outperform rating on the stock.

Separately, Weiss Ratings raised shares of National Research from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, National Research has an average rating of “Moderate Buy” and a consensus target price of $26.00.

National Research Price Performance

NASDAQ:NRC opened at $19.51 on Wednesday. National Research has a 52-week low of $11.01 and a 52-week high of $23.68. The stock has a fifty day moving average of $20.44 and a 200 day moving average of $18.32. The company has a debt-to-equity ratio of 5.48, a quick ratio of 0.52 and a current ratio of 0.52. The firm has a market capitalization of $443.85 million, a price-to-earnings ratio of 78.04 and a beta of 0.35.

National Research (NASDAQ:NRC) last announced its earnings results on Tuesday, July 28th. The company reported $0.31 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.46. National Research had a return on equity of 142.50% and a net margin of 4.18%.The business had revenue of $35.39 million for the quarter, compared to analyst estimates of $34.90 million.

National Research Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 9th. Investors of record on Friday, September 25th will be issued a $0.16 dividend. The ex-dividend date is Friday, September 25th. This represents a $0.64 annualized dividend and a yield of 3.3%. National Research’s payout ratio is 256.00%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp purchased a new position in shares of National Research during the 1st quarter worth approximately $1,531,000. Heartland Advisors Inc. raised its position in shares of National Research by 374.3% in the 1st quarter. Heartland Advisors Inc. now owns 237,147 shares of the company’s stock worth $4,027,000 after acquiring an additional 187,147 shares in the last quarter. Bank of America Corp DE lifted its stake in shares of National Research by 3.0% in the 1st quarter. Bank of America Corp DE now owns 112,468 shares of the company’s stock valued at $1,910,000 after purchasing an additional 3,323 shares during the period. Empowered Funds LLC purchased a new position in shares of National Research in the 1st quarter valued at approximately $226,000. Finally, Quantinno Capital Management LP boosted its position in shares of National Research by 61.3% during the first quarter. Quantinno Capital Management LP now owns 62,329 shares of the company’s stock valued at $1,058,000 after purchasing an additional 23,682 shares in the last quarter. 47.26% of the stock is currently owned by institutional investors.

About National Research

National Research Corp (NASDAQ: NRC), also known as NRC Health, is a healthcare analytics and performance improvement company specializing in patient and employee experience measurement. The company’s cloud-based platform enables healthcare providers to collect real-time feedback through patient satisfaction surveys, post-discharge outreach, and employee engagement tools. NRC Health integrates clinical, operational and financial data to deliver actionable insights that support quality improvement initiatives and value-based care programs.

Since its founding in the early 1990s and headquartered in Lincoln, Nebraska, National Research has expanded beyond its regional roots to serve more than 1,600 hospitals and 12,000 care sites across the United States and Canada.